Allergan Aesthetics, An AbbVie Company, Irvine, California.
University of California, Irvine, California; and.
Dermatol Surg. 2024 Sep 1;50(9S):S12-S17. doi: 10.1097/DSS.0000000000004348. Epub 2024 Jul 30.
OnabotulinumtoxinA is an injectable product that was introduced into medicine in the 1970s and has been the subject of thousands of clinical and nonclinical publications.
To review the data related to the versatility of onabotulinumtoxinA in medical aesthetics.
PubMed was searched to identify literature evaluating the effects of onabotulinumtoxinA, with preference given to randomized, placebo-controlled trials and safety meta-analyses.
OnabotulinumtoxinA is effective and safe across multiple facial indications, racial and ethnic groups, age groups, genders, and facial line severities. Patient-reported outcomes have been prioritized in aesthetic clinical trials and indicate high patient satisfaction and appearance-related psychological outcomes. Integrated safety meta-analysis and immunogenicity analyses have documented acceptable adverse event rates and low immunogenicity of onabotulinumtoxinA.
OnabotulinumtoxinA is a versatile aesthetic product supported by a strong literature base and positive physician and patient-reported outcomes that reflect a meaningful impact on patient's quality of life.
肉毒毒素 A 是一种可注射的产品,于 20 世纪 70 年代引入医学领域,已有数千篇临床和非临床文献对其进行了研究。
综述肉毒毒素 A 在医学美容领域的多功能性相关数据。
通过检索 PubMed 数据库,以确定评估肉毒毒素 A 效果的文献,优先选择随机、安慰剂对照试验和安全性荟萃分析。
肉毒毒素 A 在多种面部适应证、不同种族和民族、年龄组、性别和面部线条严重程度中均具有疗效和安全性。在美容临床试验中优先考虑患者报告的结果,并表明患者满意度高,且与外观相关的心理结果良好。综合安全性荟萃分析和免疫原性分析记录了肉毒毒素 A 可接受的不良事件发生率和低免疫原性。
肉毒毒素 A 是一种多功能的美容产品,有大量文献支持,且医生和患者的报告结果均为阳性,这反映出它对患者生活质量有重要的影响。